Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28170953 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL5503791 | 0.76 | CYP1A2 (0.56) | CYP1A2CYP2C9HSD17B10HTR6MAPT | |
| SCHEMBL14310615 | 0.76 | HSD17B10 (0.60) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL5717770 | 0.76 | HSD17B10 (1.00) | CYP1A2CYP2C9HSD17B10NOTUMKDM4E | |
| SCHEMBL22734764 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL4491047 | 0.73 | CYP1A2 (0.53) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL5274426 | 0.73 | CYP1A2 (0.76) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL1536003 | 0.72 | NOTUM (0.56) | CYP1A2CYP2C9HSD17B10NOTUMKDM4E | |
| SCHEMBL23303471 | 0.71 | CYP1A2 (0.50) | CYP1A2CYP2C9HSD17B10HTR6NOTUM | |
| SCHEMBL22734803 | 0.71 | CYP1A2 (0.50) | CYP1A2CYP2C9HSD17B10HTR6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | claimed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | claimed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | claimed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | WU YONG-JIN (US) | 2001-08-23 | — | — | US | disclosed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | disclosed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | CYP7A1, HSD17B7, CYP51A1 | CYP1A2 40/4885CYP2C9 24/4885HSD17B10 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.